Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 11 of 11 entries
Sorted by: Best Match Show Resources per page
Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome.

Indian journal of nephrology

Raghunathan V, Sethi SK, Dragon-Durey MA, Dhaliwal M, Raina R, Jha P, Bansal SB, Kher V.
PMID: 28356668
Indian J Nephrol. 2017 Mar-Apr;27(2):136-140. doi: 10.4103/0971-4065.181462.

Hypertension is common in hemolytic uremic syndrome (HUS) and often difficult to control. Local renin-angiotensin activation is believed to be an important part of thrombotic microangiopathy, leading to a vicious cycle of progressive renal injury and intractable hypertension. This...

Cite
Raghunathan V, Sethi SK, Dragon-Durey MA, et al. Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. Indian J Nephrol. 2017;27(2):136-140doi: 10.4103/0971-4065.181462.
Raghunathan, V., Sethi, S. K., Dragon-Durey, M. A., Dhaliwal, M., Raina, R., Jha, P., Bansal, S. B., & Kher, V. (2017). Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. Indian journal of nephrology, 27(2), 136-140. https://doi.org/10.4103/0971-4065.181462
Raghunathan, V, et al. "Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome." Indian journal of nephrology vol. 27,2 (2017): 136-140. doi: https://doi.org/10.4103/0971-4065.181462
Raghunathan V, Sethi SK, Dragon-Durey MA, Dhaliwal M, Raina R, Jha P, Bansal SB, Kher V. Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. Indian J Nephrol. 2017 Mar-Apr;27(2):136-140. doi: 10.4103/0971-4065.181462. PMID: 28356668; PMCID: PMC5358156.
Copy Download .nbib Format: NLM
Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s.

Cancer immunology research

Daugan MV, Revel M, Russick J, Dragon-Durey MA, Gaboriaud C, Robe-Rybkine T, Poillerat V, Grunenwald A, Lacroix G, Bougouin A, Meylan M, Verkarre V, Oudard SM, Mejean A, Vano YA, Perkins G, Validire P, Cathelineau X, Sanchez-Salas R, Damotte D, Fremeaux-Bacchi V, Cremer I, Sautès-Fridman C, Fridman WH, Roumenina LT.
PMID: 34039653
Cancer Immunol Res. 2021 Aug;9(8):891-908. doi: 10.1158/2326-6066.CIR-20-0532. Epub 2021 May 26.

The complement system plays a complex role in cancer. In clear cell renal cell carcinoma (ccRCC), local production of complement proteins drives tumor progression, but the mechanisms by which they do this are poorly understood. We found that complement...

Cite
Daugan MV, Revel M, Russick J, et al. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunol Res. 2021;9(8):891-908doi: 10.1158/2326-6066.CIR-20-0532.
Daugan, M. V., Revel, M., Russick, J., Dragon-Durey, M. A., Gaboriaud, C., Robe-Rybkine, T., Poillerat, V., Grunenwald, A., Lacroix, G., Bougouin, A., Meylan, M., Verkarre, V., Oudard, S. M., Mejean, A., Vano, Y. A., Perkins, G., Validire, P., Cathelineau, X., Sanchez-Salas, R., Damotte, D., Fremeaux-Bacchi, V., Cremer, I., Sautès-Fridman, C., Fridman, W. H., & Roumenina, L. T. (2021). Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer immunology research, 9(8), 891-908. https://doi.org/10.1158/2326-6066.CIR-20-0532
Daugan, Marie V, et al. "Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s." Cancer immunology research vol. 9,8 (2021): 891-908. doi: https://doi.org/10.1158/2326-6066.CIR-20-0532
Daugan MV, Revel M, Russick J, Dragon-Durey MA, Gaboriaud C, Robe-Rybkine T, Poillerat V, Grunenwald A, Lacroix G, Bougouin A, Meylan M, Verkarre V, Oudard SM, Mejean A, Vano YA, Perkins G, Validire P, Cathelineau X, Sanchez-Salas R, Damotte D, Fremeaux-Bacchi V, Cremer I, Sautès-Fridman C, Fridman WH, Roumenina LT. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunol Res. 2021 Aug;9(8):891-908. doi: 10.1158/2326-6066.CIR-20-0532. Epub 2021 May 26. PMID: 34039653.
Copy Download .nbib Format: NLM
Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s.

Cancer immunology research

Daugan MV, Revel M, Russick J, Dragon-Durey MA, Gaboriaud C, Robe-Rybkine T, Poillerat V, Grunenwald A, Lacroix G, Bougouin A, Meylan M, Verkarre V, Oudard SM, Mejean A, Vano YA, Perkins G, Validire P, Cathelineau X, Sanchez-Salas R, Damotte D, Fremeaux-Bacchi V, Cremer I, Sautès-Fridman C, Fridman WH, Roumenina LT.
PMID: 34039653
Cancer Immunol Res. 2021 Aug;9(8):891-908. doi: 10.1158/2326-6066.CIR-20-0532. Epub 2021 May 26.

The complement system plays a complex role in cancer. In clear cell renal cell carcinoma (ccRCC), local production of complement proteins drives tumor progression, but the mechanisms by which they do this are poorly understood. We found that complement...

Cite
Daugan MV, Revel M, Russick J, et al. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunol Res. 2021;9(8):891-908doi: 10.1158/2326-6066.CIR-20-0532.
Daugan, M. V., Revel, M., Russick, J., Dragon-Durey, M. A., Gaboriaud, C., Robe-Rybkine, T., Poillerat, V., Grunenwald, A., Lacroix, G., Bougouin, A., Meylan, M., Verkarre, V., Oudard, S. M., Mejean, A., Vano, Y. A., Perkins, G., Validire, P., Cathelineau, X., Sanchez-Salas, R., Damotte, D., Fremeaux-Bacchi, V., Cremer, I., Sautès-Fridman, C., Fridman, W. H., & Roumenina, L. T. (2021). Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer immunology research, 9(8), 891-908. https://doi.org/10.1158/2326-6066.CIR-20-0532
Daugan, Marie V, et al. "Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s." Cancer immunology research vol. 9,8 (2021): 891-908. doi: https://doi.org/10.1158/2326-6066.CIR-20-0532
Daugan MV, Revel M, Russick J, Dragon-Durey MA, Gaboriaud C, Robe-Rybkine T, Poillerat V, Grunenwald A, Lacroix G, Bougouin A, Meylan M, Verkarre V, Oudard SM, Mejean A, Vano YA, Perkins G, Validire P, Cathelineau X, Sanchez-Salas R, Damotte D, Fremeaux-Bacchi V, Cremer I, Sautès-Fridman C, Fridman WH, Roumenina LT. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunol Res. 2021 Aug;9(8):891-908. doi: 10.1158/2326-6066.CIR-20-0532. Epub 2021 May 26. PMID: 34039653.
Copy Download .nbib Format: NLM
Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s.

Cancer immunology research

Daugan MV, Revel M, Russick J, Dragon-Durey MA, Gaboriaud C, Robe-Rybkine T, Poillerat V, Grunenwald A, Lacroix G, Bougouin A, Meylan M, Verkarre V, Oudard SM, Mejean A, Vano YA, Perkins G, Validire P, Cathelineau X, Sanchez-Salas R, Damotte D, Fremeaux-Bacchi V, Cremer I, Sautès-Fridman C, Fridman WH, Roumenina LT.
PMID: 34039653
Cancer Immunol Res. 2021 Aug;9(8):891-908. doi: 10.1158/2326-6066.CIR-20-0532. Epub 2021 May 26.

The complement system plays a complex role in cancer. In clear cell renal cell carcinoma (ccRCC), local production of complement proteins drives tumor progression, but the mechanisms by which they do this are poorly understood. We found that complement...

Cite
Daugan MV, Revel M, Russick J, et al. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunol Res. 2021;9(8):891-908doi: 10.1158/2326-6066.CIR-20-0532.
Daugan, M. V., Revel, M., Russick, J., Dragon-Durey, M. A., Gaboriaud, C., Robe-Rybkine, T., Poillerat, V., Grunenwald, A., Lacroix, G., Bougouin, A., Meylan, M., Verkarre, V., Oudard, S. M., Mejean, A., Vano, Y. A., Perkins, G., Validire, P., Cathelineau, X., Sanchez-Salas, R., Damotte, D., Fremeaux-Bacchi, V., Cremer, I., Sautès-Fridman, C., Fridman, W. H., & Roumenina, L. T. (2021). Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer immunology research, 9(8), 891-908. https://doi.org/10.1158/2326-6066.CIR-20-0532
Daugan, Marie V, et al. "Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s." Cancer immunology research vol. 9,8 (2021): 891-908. doi: https://doi.org/10.1158/2326-6066.CIR-20-0532
Daugan MV, Revel M, Russick J, Dragon-Durey MA, Gaboriaud C, Robe-Rybkine T, Poillerat V, Grunenwald A, Lacroix G, Bougouin A, Meylan M, Verkarre V, Oudard SM, Mejean A, Vano YA, Perkins G, Validire P, Cathelineau X, Sanchez-Salas R, Damotte D, Fremeaux-Bacchi V, Cremer I, Sautès-Fridman C, Fridman WH, Roumenina LT. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunol Res. 2021 Aug;9(8):891-908. doi: 10.1158/2326-6066.CIR-20-0532. Epub 2021 May 26. PMID: 34039653.
Copy Download .nbib Format: NLM
Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade.

Cancer immunology research

Daugan MV, Revel M, Thouenon R, Dragon-Durey MA, Robe-Rybkine T, Torset C, Merle NS, Noé R, Verkarre V, Oudard SM, Mejean A, Validire P, Cathelineau X, Sanchez-Salas R, Pickering MC, Cremer I, Mansuet-Lupo A, Alifano M, Sautès-Fridman C, Damotte D, Fridman WH, Roumenina LT.
PMID: 34039652
Cancer Immunol Res. 2021 Aug;9(8):909-925. doi: 10.1158/2326-6066.CIR-20-0787. Epub 2021 May 26.

The complement system is a powerful and druggable innate immune component of the tumor microenvironment. Nevertheless, it is challenging to elucidate the exact mechanisms by which complement affects tumor growth. In this study, we examined the processes by which...

Cite
Daugan MV, Revel M, Thouenon R, et al. Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. Cancer Immunol Res. 2021;9(8):909-925doi: 10.1158/2326-6066.CIR-20-0787.
Daugan, M. V., Revel, M., Thouenon, R., Dragon-Durey, M. A., Robe-Rybkine, T., Torset, C., Merle, N. S., Noé, R., Verkarre, V., Oudard, S. M., Mejean, A., Validire, P., Cathelineau, X., Sanchez-Salas, R., Pickering, M. C., Cremer, I., Mansuet-Lupo, A., Alifano, M., Sautès-Fridman, C., Damotte, D., Fridman, W. H., & Roumenina, L. T. (2021). Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. Cancer immunology research, 9(8), 909-925. https://doi.org/10.1158/2326-6066.CIR-20-0787
Daugan, Marie V, et al. "Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade." Cancer immunology research vol. 9,8 (2021): 909-925. doi: https://doi.org/10.1158/2326-6066.CIR-20-0787
Daugan MV, Revel M, Thouenon R, Dragon-Durey MA, Robe-Rybkine T, Torset C, Merle NS, Noé R, Verkarre V, Oudard SM, Mejean A, Validire P, Cathelineau X, Sanchez-Salas R, Pickering MC, Cremer I, Mansuet-Lupo A, Alifano M, Sautès-Fridman C, Damotte D, Fridman WH, Roumenina LT. Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. Cancer Immunol Res. 2021 Aug;9(8):909-925. doi: 10.1158/2326-6066.CIR-20-0787. Epub 2021 May 26. PMID: 34039652.
Copy Download .nbib Format: NLM
Interstitial Lung Disease-Complicated Anti-MDA5 Antibody in Clinically Amyopathic Dermatomyositis Patients: Report of Two Cases With Distinct Clinical Features.

Frontiers in medicine

Pacot L, Pouchot J, De Prost N, Senant M, Tartour E, Le Pimpec-Barthes F, Israel-Biet D, Dragon-Durey MA.
PMID: 32211415
Front Med (Lausanne). 2020 Mar 10;7:77. doi: 10.3389/fmed.2020.00077. eCollection 2020.

Two patients presented simultaneously to our hospital with distinct clinical features associated with the presence of anti-MDA5 antibodies: the first one was admitted for a skin rash resembling to a toxic epidermal necrosis (Lyell syndrome) and the second one...

Cite
Pacot L, Pouchot J, De Prost N, et al. Interstitial Lung Disease-Complicated Anti-MDA5 Antibody in Clinically Amyopathic Dermatomyositis Patients: Report of Two Cases With Distinct Clinical Features. Front Med (Lausanne). 2020;7:77doi: 10.3389/fmed.2020.00077.
Pacot, L., Pouchot, J., De Prost, N., Senant, M., Tartour, E., Le Pimpec-Barthes, F., Israel-Biet, D., & Dragon-Durey, M. A. (2020). Interstitial Lung Disease-Complicated Anti-MDA5 Antibody in Clinically Amyopathic Dermatomyositis Patients: Report of Two Cases With Distinct Clinical Features. Frontiers in medicine, 777. https://doi.org/10.3389/fmed.2020.00077
Pacot, Laurence, et al. "Interstitial Lung Disease-Complicated Anti-MDA5 Antibody in Clinically Amyopathic Dermatomyositis Patients: Report of Two Cases With Distinct Clinical Features." Frontiers in medicine vol. 7 (2020): 77. doi: https://doi.org/10.3389/fmed.2020.00077
Pacot L, Pouchot J, De Prost N, Senant M, Tartour E, Le Pimpec-Barthes F, Israel-Biet D, Dragon-Durey MA. Interstitial Lung Disease-Complicated Anti-MDA5 Antibody in Clinically Amyopathic Dermatomyositis Patients: Report of Two Cases With Distinct Clinical Features. Front Med (Lausanne). 2020 Mar 10;7:77. doi: 10.3389/fmed.2020.00077. eCollection 2020. PMID: 32211415; PMCID: PMC7076087.
Copy Download .nbib Format: NLM
Quality and best practice in medical laboratories: specific requests for autoimmunity testing.

Auto- immunity highlights

Sack U, Bossuyt X, Andreeva H, Antal-Szalmás P, Bizzaro N, Bogdanos D, Borzova E, Conrad K, Dragon-Durey MA, Eriksson C, Fischer K, Haapala AM, Heijnen I, Herold M, Klotz W, Kozmar A, Tesija Kuna A, López Hoyos M, Malkov VA, Musset L, Nagy E, Rönnelid J, Shoenfeld Y, Sundic T, Tsirogianni A, Uibo R, Rego Sousa MJ, Damoiseaux J.
PMID: 32883353
Auto Immun Highlights. 2020 Sep 03;11(1):12. doi: 10.1186/s13317-020-00134-0.

Special conditions associated with laboratory autoimmune testing are not well compatible with recent developments in regulatory frameworks such as EN/ISO 15189 accreditation or in vitro diagnostic medical device regulation (IVD-R). In addition, international recommendations, guidelines and disease criteria are...

Cite
Sack U, Bossuyt X, Andreeva H, et al. Quality and best practice in medical laboratories: specific requests for autoimmunity testing. Auto Immun Highlights. 2020;11(1):12doi: 10.1186/s13317-020-00134-0.
Sack, U., Bossuyt, X., Andreeva, H., Antal-Szalmás, P., Bizzaro, N., Bogdanos, D., Borzova, E., Conrad, K., Dragon-Durey, M. A., Eriksson, C., Fischer, K., Haapala, A. M., Heijnen, I., Herold, M., Klotz, W., Kozmar, A., Tesija Kuna, A., López Hoyos, M., Malkov, V. A., Musset, L., Nagy, E., Rönnelid, J., Shoenfeld, Y., Sundic, T., Tsirogianni, A., Uibo, R., Rego Sousa, M. J., Damoiseaux, J. (2020). Quality and best practice in medical laboratories: specific requests for autoimmunity testing. Auto- immunity highlights, 11(1), 12. https://doi.org/10.1186/s13317-020-00134-0
Sack, Ulrich, et al. "Quality and best practice in medical laboratories: specific requests for autoimmunity testing." Auto- immunity highlights vol. 11,1 (2020): 12. doi: https://doi.org/10.1186/s13317-020-00134-0
Sack U, Bossuyt X, Andreeva H, Antal-Szalmás P, Bizzaro N, Bogdanos D, Borzova E, Conrad K, Dragon-Durey MA, Eriksson C, Fischer K, Haapala AM, Heijnen I, Herold M, Klotz W, Kozmar A, Tesija Kuna A, López Hoyos M, Malkov VA, Musset L, Nagy E, Rönnelid J, Shoenfeld Y, Sundic T, Tsirogianni A, Uibo R, Rego Sousa MJ, Damoiseaux J. Quality and best practice in medical laboratories: specific requests for autoimmunity testing. Auto Immun Highlights. 2020 Sep 03;11(1):12. doi: 10.1186/s13317-020-00134-0. PMID: 32883353; PMCID: PMC7470612.
Copy Download .nbib Format: NLM
Eculizumab for atypical hemolytic-uremic syndrome in India: First report from India and the challenges faced.

Indian journal of nephrology

Sethi SK, Rohatgi S, Dragon-Durey MA, Raghunathan V, Dhaliwal M, Rawat A, Jha P, Bansal SB, Raina R, Kher V.
PMID: 28182046
Indian J Nephrol. 2017 Jan-Feb;27(1):58-61. doi: 10.4103/0971-4065.179369.

Much progress has been made in understanding the pathophysiology and treatment of atypical hemolytic uremic syndrome (aHUS). Plasma therapy is the mainstay of treatment for aHUS. The availability of the first effective anti-complement therapeutic agent, eculizumab, has dramatically changed...

Cite
Sethi SK, Rohatgi S, Dragon-Durey MA, et al. Eculizumab for atypical hemolytic-uremic syndrome in India: First report from India and the challenges faced. Indian J Nephrol. 2017;27(1):58-61doi: 10.4103/0971-4065.179369.
Sethi, S. K., Rohatgi, S., Dragon-Durey, M. A., Raghunathan, V., Dhaliwal, M., Rawat, A., Jha, P., Bansal, S. B., Raina, R., & Kher, V. (2017). Eculizumab for atypical hemolytic-uremic syndrome in India: First report from India and the challenges faced. Indian journal of nephrology, 27(1), 58-61. https://doi.org/10.4103/0971-4065.179369
Sethi, S K, et al. "Eculizumab for atypical hemolytic-uremic syndrome in India: First report from India and the challenges faced." Indian journal of nephrology vol. 27,1 (2017): 58-61. doi: https://doi.org/10.4103/0971-4065.179369
Sethi SK, Rohatgi S, Dragon-Durey MA, Raghunathan V, Dhaliwal M, Rawat A, Jha P, Bansal SB, Raina R, Kher V. Eculizumab for atypical hemolytic-uremic syndrome in India: First report from India and the challenges faced. Indian J Nephrol. 2017 Jan-Feb;27(1):58-61. doi: 10.4103/0971-4065.179369. PMID: 28182046; PMCID: PMC5255992.
Copy Download .nbib Format: NLM
A rare complication of pauci-immune crescentic glomerulonephritis in a child: Questions.

Pediatric nephrology (Berlin, Germany)

Sethi SK, Rana A, Bansal SB, Rana A, Yadav DK, Soni K, Dragon-Durey MA, Raina R, Kher V.
PMID: 33057768
Pediatr Nephrol. 2021 Jul;36(7):1947-1948. doi: 10.1007/s00467-020-04784-0. Epub 2020 Oct 15.

No abstract available.

Cite
Sethi SK, Rana A, Bansal SB, et al. A rare complication of pauci-immune crescentic glomerulonephritis in a child: Questions. Pediatr Nephrol. 2020;36(7):1947-1948doi: 10.1007/s00467-020-04784-0.
Sethi, S. K., Rana, A., Bansal, S. B., Rana, A., Yadav, D. K., Soni, K., Dragon-Durey, M. A., Raina, R., & Kher, V. (2021). A rare complication of pauci-immune crescentic glomerulonephritis in a child: Questions. Pediatric nephrology (Berlin, Germany), 36(7), 1947-1948. https://doi.org/10.1007/s00467-020-04784-0
Sethi, Sidharth Kumar, et al. "A rare complication of pauci-immune crescentic glomerulonephritis in a child: Questions." Pediatric nephrology (Berlin, Germany) vol. 36,7 (2021): 1947-1948. doi: https://doi.org/10.1007/s00467-020-04784-0
Sethi SK, Rana A, Bansal SB, Rana A, Yadav DK, Soni K, Dragon-Durey MA, Raina R, Kher V. A rare complication of pauci-immune crescentic glomerulonephritis in a child: Questions. Pediatr Nephrol. 2021 Jul;36(7):1947-1948. doi: 10.1007/s00467-020-04784-0. Epub 2020 Oct 15. PMID: 33057768.
Copy Download .nbib Format: NLM
A rare complication of pauci-immune crescentic glomerulonephritis in a child: Answers.

Pediatric nephrology (Berlin, Germany)

Sethi SK, Rana A, Bansal SB, Rana A, Yadav DK, Soni K, Dragon-Durey MA, Raina R, Kher V.
PMID: 33057767
Pediatr Nephrol. 2021 Jul;36(7):1949-1952. doi: 10.1007/s00467-020-04786-y. Epub 2020 Oct 15.

No abstract available.

Cite
Sethi SK, Rana A, Bansal SB, et al. A rare complication of pauci-immune crescentic glomerulonephritis in a child: Answers. Pediatr Nephrol. 2020;36(7):1949-1952doi: 10.1007/s00467-020-04786-y.
Sethi, S. K., Rana, A., Bansal, S. B., Rana, A., Yadav, D. K., Soni, K., Dragon-Durey, M. A., Raina, R., & Kher, V. (2021). A rare complication of pauci-immune crescentic glomerulonephritis in a child: Answers. Pediatric nephrology (Berlin, Germany), 36(7), 1949-1952. https://doi.org/10.1007/s00467-020-04786-y
Sethi, Sidharth Kumar, et al. "A rare complication of pauci-immune crescentic glomerulonephritis in a child: Answers." Pediatric nephrology (Berlin, Germany) vol. 36,7 (2021): 1949-1952. doi: https://doi.org/10.1007/s00467-020-04786-y
Sethi SK, Rana A, Bansal SB, Rana A, Yadav DK, Soni K, Dragon-Durey MA, Raina R, Kher V. A rare complication of pauci-immune crescentic glomerulonephritis in a child: Answers. Pediatr Nephrol. 2021 Jul;36(7):1949-1952. doi: 10.1007/s00467-020-04786-y. Epub 2020 Oct 15. PMID: 33057767.
Copy Download .nbib Format: NLM
Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade.

Cancer immunology research

Daugan MV, Revel M, Thouenon R, Dragon-Durey MA, Robe-Rybkine T, Torset C, Merle NS, Noé R, Verkarre V, Oudard SM, Mejean A, Validire P, Cathelineau X, Sanchez-Salas R, Pickering MC, Cremer I, Mansuet-Lupo A, Alifano M, Sautès-Fridman C, Damotte D, Fridman WH, Roumenina LT.
PMID: 34039652
Cancer Immunol Res. 2021 Aug;9(8):909-925. doi: 10.1158/2326-6066.CIR-20-0787. Epub 2021 May 26.

The complement system is a powerful and druggable innate immune component of the tumor microenvironment. Nevertheless, it is challenging to elucidate the exact mechanisms by which complement affects tumor growth. In this study, we examined the processes by which...

Cite
Daugan MV, Revel M, Thouenon R, et al. Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. Cancer Immunol Res. 2021;9(8):909-925doi: 10.1158/2326-6066.CIR-20-0787.
Daugan, M. V., Revel, M., Thouenon, R., Dragon-Durey, M. A., Robe-Rybkine, T., Torset, C., Merle, N. S., Noé, R., Verkarre, V., Oudard, S. M., Mejean, A., Validire, P., Cathelineau, X., Sanchez-Salas, R., Pickering, M. C., Cremer, I., Mansuet-Lupo, A., Alifano, M., Sautès-Fridman, C., Damotte, D., Fridman, W. H., & Roumenina, L. T. (2021). Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. Cancer immunology research, 9(8), 909-925. https://doi.org/10.1158/2326-6066.CIR-20-0787
Daugan, Marie V, et al. "Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade." Cancer immunology research vol. 9,8 (2021): 909-925. doi: https://doi.org/10.1158/2326-6066.CIR-20-0787
Daugan MV, Revel M, Thouenon R, Dragon-Durey MA, Robe-Rybkine T, Torset C, Merle NS, Noé R, Verkarre V, Oudard SM, Mejean A, Validire P, Cathelineau X, Sanchez-Salas R, Pickering MC, Cremer I, Mansuet-Lupo A, Alifano M, Sautès-Fridman C, Damotte D, Fridman WH, Roumenina LT. Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. Cancer Immunol Res. 2021 Aug;9(8):909-925. doi: 10.1158/2326-6066.CIR-20-0787. Epub 2021 May 26. PMID: 34039652.
Copy Download .nbib Format: NLM
Showing 1 to 11 of 11 entries